IL-6, but not TNF-α, increases plasma YKL-40 in human subjects

Cytokine

Volumn 55, Issue 1, 2011, Pages 152-155

  Nielsen, Anders R ^a   Plomgaard, Peter ^a   Krabbe, Karen S ^a   Johansen, Julia S ^b   Pedersen, Bente K ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cytokines; IL 6; TNF ; YKL 40

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN YKL 40; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 6; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TASONERMIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REFERENCE VALUE;

ADULT; GLYCOPROTEINS; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; LECTINS; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79956341474     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.03.014     Document Type: Article

References (43)

1. Areshkov P.A., Kavsan V.M. Chitinase 3-like protein 2 (CHI3L2, YKL-39) activates phosphorylation of extracellular signal-regulated kinases ERK1/ERK2 in human embryonic kidney (HEK293) and human glioblastoma (U87 MG) cells. Tsitol Genet 2010, 44:3-9.
2. Biro L., Domjan G., Falus A., Jakab L., Cseh K., Kalabay L., et al. Cytokine regulation of the acute-phase protein levels in multiple myeloma. Eur J Clin Invest 1998, 28:679-686.
3. Bonneh-Barkay D., Bissel S.J., Wang G., Fish K.N., Nicholl G.C., Darko S.W., et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol 2008, 173:130-143.
4. Bussink A.P., Speijer D., Aerts J.M., Boot R.G. Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics 2007, 177:959-970.
5. Castell J.V., Andus T., Kunz D., Heinrich P.C. Interleukin-6. The major regulator of acute-phase protein synthesis in man and rat. Ann NY Acad Sci 1989, 557:87-99.
6. Castell J.V., Gomez-Lechon M.J., David M., Fabra R., Trullenque R., Heinrich P.C. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990, 12:1179-1186.
7. Chupp G.L., Lee C.G., Jarjour N., Shim Y.M., Holm C.T., He S., et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007, 357:2016-2027.
8. De C.F., Gaufillier S., Bonnaud A., Sabatini M., Lesur C., Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001, 285:926-931.
9. Falus A., Rokita H., Walcz E., Brozik M., Hidvegi T., Meretey K. Hormonal regulation of complement biosynthesis in human cell lines-II. Upregulation of the biosynthesis of complement components C3, factor B and C1 inhibitor by interleukin-6 and interleukin-1 in human hepatoma cell line. Mol Immunol 1990, 27:197-201.
10. Fontana R.J., Dienstag J.L., Bonkovsky H.L., Sterling R.K., Naishadham D., Goodman Z.D., et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010, 59:1401-1409.
11. Harvey S., Weisman M., O'Dell J., Scott T., Krusemeier M., Visor J., et al. Chondrex: new marker of joint disease. Clin Chem 1998, 44:509-516.
12. Houston D.R., Recklies A.D., Krupa J.C., van Aalten D.M. Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes. J Biol Chem 2003, 278:30206-30212.
13. Johansen J.S., Christoffersen P., Moller S., Price P.A., Henriksen J.H., Garbarsch C., et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000, 32:911-920.
14. Johansen J.S., Jensen B.V., Roslind A., Nielsen D., Price P.A. Serum YKL-40, a new prognostic biomarker in cancer patients?. Cancer Epidemiol Biomarkers Prev 2006, 15:194-202.
15. Johansen J.S., Krabbe K.S., Moller K., Pedersen B.K. Circulating YKL-40 levels during human endotoxaemia. Clin Exp Immunol 2005, 140:343-348.
16. Johansen J.S., Pedersen A.N., Schroll M., Jorgensen T., Pedersen B.K., Bruunsgaard H. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol 2008, 151:260-266.
17. Kastrup J., Johansen J.S., Winkel P., Hansen J.F., Hildebrandt P., Jensen G.B., et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 2009, 30:1066-1072.
18. Katz Y., Guterman M., Lahat E. Regulation of synthesis of complement proteins in HEp2 cells. Clin Immunol Immunopathol 1993, 67:117-123.
19. Kjaergaard A.D., Bojesen S.E., Johansen J.S., Nordestgaard B.G. Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 2010, 68:672-680.
20. Krabbe K.S., Pedersen M., Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 2004, 39:687-699.
21. Kronborg G., Ostergaard C., Weis N., Nielsen H., Obel N., Pedersen S.S., et al. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand J Infect Dis 2002, 34:323-326.
22. Letuve S., Kozhich A., Arouche N., Grandsaigne M., Reed J., Dombret M.C., et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 2008, 181:5167-5173.
23. Ling H., Recklies A.D. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 2004, 380:651-659.
24. Malinda K.M., Ponce L., Kleinman H.K., Shackelton L.M., Millis A.J. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999, 250:168-173.
25. Matsumoto T., Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters. Clin Exp Rheumatol 2001, 19:655-660.
26. Nielsen A.R., Erikstrup C., Johansen J.S., Fischer C.P., Plomgaard P., Krogh-Madsen R., et al. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 2008, 57:3078-3082.
27. Nishikawa K.C., Millis A.J. Gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003, 287:79-87.
28. Nojgaard C., Johansen J.S., Christensen E., Skovgaard L.T., Price P.A., Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003, 39:179-186.
29. Nordenbaek C., Johansen J.S., Junker P., Borregaard N., Sorensen O., Price P.A. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis 1999, 180:1722-1726.
30. Plomgaard P., Bouzakri K., Krogh-Madsen R., Mittendorfer B., Zierath J.R., Pedersen B.K. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005, 54:2939-2945.
31. Rathcke C.N., Johansen J.S., Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 2006, 55:53-59.
32. Recklies A.D., White C., Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 2002, 365:119-126.
33. Rehli M., Krause S.W., Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997, 43:221-225.
34. Rehli M., Niller H.H., Ammon C., Langmann S., Schwarzfischer L., Andreesen R., et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003, 278:44058-44067.
35. Ringsholt M., Hogdall E.V., Johansen J.S., Price P.A., Christensen L.H. YKL-40 protein expression in normal adult human tissues-an immunohistochemical study. J Mol Histol 2007, 38:33-43.
36. Shao R., Hamel K., Petersen L., Cao Q.J., Arenas R.B., Bigelow C., et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009, 28:4456-4468.
37. Starkie R., Ostrowski S.R., Jauffred S., Febbraio M., Pedersen B.K. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 2003, 17:884-886.
38. van Gameren M.M., Willemse P.H., Mulder N.H., Limburg P.C., Groen H.J., Vellenga E., et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994, 84:1434-1441.
39. van Hall G., Steensberg A., Sacchetti M., Fischer C., Keller C., Schjerling P., et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 2003, 88:3005-3010.
40. Vind I., Johansen J.S., Price P.A., Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003, 38:599-605.
41. Volck B., Price P.A., Johansen J.S., Sorensen O., Benfield T.L., Nielsen H.J., et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998, 110:351-360.
42. Weber J., Yang J.C., Topalian S.L., Parkinson D.R., Schwartzentruber D.S., Ettinghausen S.E., et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993, 11:499-506.
43. Zuraw B.L., Lotz M. Regulation of the hepatic synthesis of C1 inhibitor by the hepatocyte stimulating factors interleukin 6 and interferon gamma. J Biol Chem 1990, 265:12664-12670.